



Bll is a non-profit foundation funded with 470M EUR from the Novo Nordisk Foundation



BII is different from The Novo Foundation and Novo Holding - both in terms of focus area and funding type.

novo nordisk fonden	BIBioInnovation	novo holdings Investors in life science	
Build translational capacity at Research Institutions & Clinics	Mature projects through Discovery, Acceleration & Incubation	Build the Team and take active ownership in company portfolio	
Grants	Grants & Convertible loans	Investments	



BII helps start-ups become investment ready by bridging the gap between academia and business.







WHO is BII for?

BII's programs are for early life science entrepreneurs and established organizations who want to support the life science ecosystem.

BII is primarily engaged with start-ups and partners within **three key areas** of the life science industry.

BII



Knowledge


Network

Funding


Infrastructure

We select promising start-ups and support them by offering **four essentials** for success.

BI



Every BII start-up gets their own BII anchor: an expert responsible for supporting their business development with knowledge, tools and mentorship.



Our start-ups benefit from our **network** within the eco-system. Our collaboration partners take a starting point in the start-up's journey and needs.



Faculty Grant 36 months

Up to EUR 2.5M



Our start-ups get access to **funding** via our programs to help them accelerate their business.



Creation House Convertible Ioan 18 months

Up to EUR 1.3M





Our start-ups get access to our community and **Infrastructure** which includes office space, laboratory facilities and technical platforms.



Selection


process



Application process - BII shares the due diligence reports with shortlisted applicants



Application process - Invited applicants pitch to Europe's top Investors




Being a part of BII




The Venture Lab Program provides the tools for entrepreneurs

Crunches to build a business plan




Halos to deal with psychological challenges as founders





BII Partners

Helping us bring research to market



BII has a **diverse portfolio** of promising start-ups within BioIndustrials.



	Proof of Concept Stage	Optimization Stage	Application Stage	Scaling Stage	Commercial stage
BioIndustrials					
Materials			CELIUGY"		
Carbon Capture		() second circle			
Animal Health	Vesio	cula (III mycropt			
Food and Beverages			EvodiaBio	HROMOLOGICS	
Platform technology	Kea	sling	«ENDURO	starine	
Aqua culture					
Ag-Tech	Kristiansen			Sundew	BI

BII has a **diverse portfolio** of promising start-ups within Therapeutics.





An international portfolio

STIMULIVER





Liver implant

Stimuliver is developing a liver implant which uses lab engineered liver tissue that will be placed underneath the skin to 'top up' the patient's reduced liver function. Liver tissue will be produced from human stem cells, providing a scalable and renewable source of human liver tissue.

BOOST Pharma

Treating the untreatable





Cell therapy treatments for Osteogenesis Imperfecta.

In vitro expanded mesenchymal stem cells to treat severe Osteogenesis Imperfecta (OI) or Brittle Bone Disease in children and unborn babies

Non-hormonal contraceptive

CIROLE biomedical



BII BioInnovation Institute





CRBIT



Remote Parkinson's disease monitoring

Device agnostic, AI-powered solution for the personalization of treatment of Parkinson's patients through continuous and objective remote disease state monitoring.



66

start-ups from 2018-2021

Start-ups 38 received external funding

Seed

> 1M EUR

grants


Series A investments investments > 10M EUR

5

17 76 Minor Additional


investments < 1M EUR

Granted funding by BII vs. granted external funding (accumulated)



BII funding Total external funding

Split between loans, grants and investments



of portfolio have raised external funding since 2018 147M

EUR raised in external funding by our portfolio

3.2x

external funding leverage in average across portfolio

23%

Of start-ups in Creation House were also part of Venture Lab

opwext application deadline:

Venture Lab

BioInnovation

24th February, 2022

Scan to read more:



